Medtech VCs Show Steady Hand With Dollars Invested in 2013
This article was originally published in Start Up
Executive Summary
Despite contraction in the number of funds and VC firms investing in life sciences, 2013 was a strong year for private investing in medtech, with private investors putting $2.54 million into 129 medical device deals, according to Informa’s Strategic Transactions. Looking at where investors placed their money revealed some emerging trends.
You may also be interested in...
Venture Investors See Opportunity In Ophthalmology
A review of venture capital investments in ophthalmology-focused biotechs and medtechs over the past five years. Data from Informa's Strategic Transactions.
Toward Spectacle-Free Cataract Surgery
After a lull, or at least a single-minded focus on femtosecond lasers for a time, refractive surgery has gotten exciting again: the drive to spectacle-free outcomes for cataract patients (who have aged-out of their eligibility for other refractive procedures) is calling for solutions that offer precision and accuracy at every stage of treatment. Start-ups coming up with the solutions will be serving some gigantic markets.
ElectroCore Aims To Bring Neurostimulation To The Masses, Beginning With Headache
Armed with financing from a syndicate including Merck’s Global Health Innovation Fund, electroCore is pressing ahead with pivotal trials in several headache indications, with other neural and immune conditions to follow. The company believes its noninvasive vagus nerve stimulator that is self-administered by the patient could potentially upturn treatment paradigms.